Radiation Induced Oral Mucositis in Prostate Cancer – Epidemiology Forecast – 2036

Key Highlights

Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Radiotherapy is a cornerstone of prostate cancer management, with an optimal utilization rate of about 60%. As a result, a substantial and growing survivorship population is exposed to pelvic irradiation.

The growing population of long-term prostate cancer survivors, driven by increased early-stage detection and expanded use of active surveillance, is sustaining and expanding the pool of patients at risk for radiation-induced toxicities, creating a persistent clinical need and potential market for supportive interventions.

Radiotherapy utilization is rising in both non-metastatic and metastatic settings, with advanced techniques like IMRT and SBRT becoming dominant, while conventional modalities decline; this trend toward higher precision and wider adoption indirectly increases the demand for managing late-onset mucositis and related pelvic radiation complications.

Across the 7MM, radiotherapy utilization and prostate cancer prevalence show notable variation: the US and UK report higher rates of radiotherapy use in localized disease (~42–49%) compared with Germany (~29%) and Japan (~16–17% for early-stage), while metastatic cases in the UK (~16%) are proportionally higher than in EU4 and Japan, reflecting country-specific screening practices, early detection rates, and clinical management approaches.

Radiation Induced Oral Mucositis in Prostate Cancer Infection Epidemiology forecast

2025 Radiation-Induced Mucositis in Prostate Cancer Among Radiotherapy Modalities: ~1,170,000

2036 Radiation-Induced Mucositis in Prostate Cancer Among Radiotherapy Modalities:

~ 1,416,000

Radiation Induced Oral Mucositis in Prostate Cancer Growth Rate (2026–2036): 1.6% CAGR

DelveInsight's ‘Radiation Induced Oral Mucositis in Prostate Cancer – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Radiation Induced Oral Mucositis in Prostate Cancer , historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Radiation Induced Oral Mucositis in Prostate Cancer Understanding and Treatment Algorithm

Radiation Induced Oral Mucositis in Prostate Cancer Overview and Diagnosis

Radiation-induced toxicities form a spectrum of mucosal and organ injury after radiotherapy, especially in pelvic cancers. It often begins with mucositis, an inflammatory response of the oral and gastrointestinal mucosa that is painful but usually temporary. Pelvic radiation may progress to radiation proctitis, causing diarrhea, urgency, and bleeding acutely or chronic complications such as strictures and fistulas. Inflammation may also involve the bladder (radiation cystitis) with urinary symptoms, or the colon (radiation colitis), which can develop months to years after treatment and range from acute to chronic disease.

Risk factors for radiation-induced mucositis include radiation dose, treatment area, and delivery method. Doses below 45 Gy are linked to minimal long-term effects, while 45–70 Gy increases complications and doses above 70 Gy can cause severe, lasting tissue damage. Diagnosis involves blood and stool tests to detect infection or bleeding, endoscopic procedures such as flexible sigmoidoscopy or colonoscopy with biopsy to assess intestinal injury, as well as STI testing, urinalysis, and cystoscopy to evaluate urinary tract involvement.

Further details are provided in the report.

Radiation Induced Oral Mucositis in Prostate Cancer Epidemiology

Key Findings from Radiation Induced Oral Mucositis in Prostate Cancer Epidemiological Analysis and Forecast

In 2025, the total cases of prevalent prostate cancer was 7,700,000 in the 7MM. These cases are expected to increase during the forecast period.

As per DelveInsight’s estimates, In US, In prostate cancer the radiotherapy utilization is highest in localized disease, accounting for 270,000 cases in 2025 and projected to increase by 2036. This is followed by nmCSPC/nmHSPC, with 254,000 cases in 2025, expected to rise to by 2036.

IMRT is currently the most widely adopted and advanced form of radiotherapy in prostate cancer, accounting for the highest number of treated cases at 390,000 in 2025 and projected to increase by 2036.

This growth reflects its favorable toxicity profile and ability to deliver higher, more conformal doses. As IMRT continues to replace older techniques, its expanding use is expected to drive the overall radiotherapy-treated population and, consequently, the pool of patients at risk for radiation-related pelvic toxicities.

Scope of the Report

The report covers a segment of a descriptive overview of Radiation Induced Oral Mucositis in Prostate Cancer , explaining their causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Radiation Induced Oral Mucositis in Prostate Cancer Patient population forecast

Report Key Strengths

Epidemiology-based (Epi-based) bottom-up forecasting

11-year forecast

Patient Burden trends (by geography)

FAQs

What are the disease risks, burdens, and unmet needs of Radiation Induced Oral Mucositis in Prostate Cancer ? What will be the growth opportunities across the 7MM concerning the patient population with Radiation Induced Oral Mucositis in Prostate Cancer ?

What is the historical and forecasted Radiation Induced Oral Mucositis in Prostate Cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges. Show more